KB
Kenjockety Biotechnology, Inc.
The startup develops bispecific antibodies (BsAbs) that target efflux pumps and tumor-associated antigens (TAAs) to enhance the specificity of cancer treatments. This approach aims to improve therapeutic efficacy for patients facing drug-resistant tumors by selectively targeting cancer cells while sparing normal cells.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops bispecific antibodies (BsAbs) that target efflux pumps and tumor-associated antigens (TAAs) to enhance the specificity of cancer treatments. This approach aims to improve therapeutic efficacy for patients facing drug-resistant tumors by selectively targeting cancer cells while sparing normal cells.